Hua Guoqiang, Kolesnick Richard
Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Handb Exp Pharmacol. 2013;216(216):29-54. doi: 10.1007/978-3-7091-1511-4_2.
Acid sphingomyelinase (ASMase) is a key initiator of sphingomyelin/ceramide signal transduction activated by many stress stimuli. Over the past two decades, much progress has been made in defining the clinical relevance of sphingomyelin/ceramide signaling in numerous diseases using ASMase knockout mice. Organs that operate this pathway are numerous and the disease states regulated are diverse, with ceramide generation governing injury in tumor, gut, ovary, brain, lung, heart, liver, and during infection. This chapter emphasizes evolutionary conservation of sphingolipid stress signaling and mammalian adaptations that permit transduction of organotypic responses. Recognition that the sphingomyelin/ceramide transducer calibrates extent of tissue injury, ultimately acting as a molecular switch that determines organ fate, is driving development of new pharmacologic concepts and tools to intervene therapeutically.
酸性鞘磷脂酶(ASMase)是由多种应激刺激激活的鞘磷脂/神经酰胺信号转导的关键启动因子。在过去二十年中,使用ASMase基因敲除小鼠在确定鞘磷脂/神经酰胺信号在众多疾病中的临床相关性方面取得了很大进展。运作该信号通路的器官众多,所调节的疾病状态也多种多样,神经酰胺的产生在肿瘤、肠道、卵巢、脑、肺、心脏、肝脏以及感染过程中均参与损伤调控。本章着重介绍鞘脂应激信号的进化保守性以及允许转导器官特异性反应的哺乳动物适应性。认识到鞘磷脂/神经酰胺信号转导器可校准组织损伤程度,最终作为决定器官命运的分子开关,这推动了新的药理学概念和治疗干预工具的发展。